|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
16.500 -0.060 (-0.362%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 20,376,519 | 4.896% | 41,498,325 | 40,909,878 | 41,248,505 | 43,811,385 |
| Cost of Sales | (10,288,189) | 1.627% | (20,800,103) | (21,365,574) | (21,595,309) | (23,169,690) |
| Gross Profit | 10,088,330 | 8.453% | 20,698,222 | 19,544,304 | 19,653,196 | 20,641,695 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (28,123) | -2.126% | (125,175) | (110,631) | (131,927) | (65,369) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 1,135,354 | 22.126% | 1,923,979 | 1,643,839 | 2,184,849 | 1,835,146 | |
| Profit / (Loss) before Taxation | 2,586,571 | -4.852% | 5,111,984 | 4,169,281 | 3,276,908 | 4,580,552 | |
| Taxation | (437,643) | -29.215% | (864,054) | (656,841) | (369,504) | (626,918) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (427,460) | 7.336% | (877,368) | (742,554) | (508,798) | (216,659) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,721,468 | 1.146% | 3,370,562 | 2,769,886 | 2,398,606 | 3,736,975 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 472,162 | -3.508% | 964,847 | 1,058,705 | 961,186 | 681,172 |
| Depreciation & Amortisation | 1,878,267 | 8.015% | 3,847,990 | 3,242,146 | 3,202,753 | 2,496,331 |
| Directors' Emoluments | -- | -- | 42,537 | 21,284 | 48,086 | 50,007 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 65.000 | 1.563% | 127.000 | 104.000 | 90.000 | 143.000 |
| DPS (cts) | 0.000 | -- | 39.000 | 32.000 | 27.000 | 42.000 |
| Dividend Payout Ratio (%) | -- | -- | 30.709% | 30.769% | 30.000% | 29.371% |
| Cash flow per share ($) | -- | -- | 1.970 | 1.677 | 1.279 | 1.618 |
| NBV per share ($) | 18.447 | -- | 18.451 | 17.766 | 17.081 | 16.665 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,721,468 |
| %Change | 1.146% |
| EPS / (LPS) | RMB 0.650 |
| NBV Per Share (¥) | RMB 18.447 |